ArticleTranslational cancer research2026
Tumor histologic subtypes and stage impact the risk of cardiovascular diseases death in lung cancer patients after chemotherapy or radiotherapy: a population-based study.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Traditional cardiovascular diseases (CVDs) risk factors have been the focus of previous research in lung cancer patients treated with chemotherapy (CT) or radiotherapy (RT). However, the role of tumor characteristics in CVD death risk remains unclear. Therefore, we explored this association in CT/RT-treated lung cancer patients. Methods: The study enrolled CT/RT-treated lung cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database [2002-2017]. The CVD death risk was estimated using Fine-Gray competing risk model. To adjust for potential confounders, we conducted sensitivity analyses. Subgroup analyses and interaction tests were performed to assess the robustness of the findings. A nomogram was constructed to visually demonstrate the influence of tumor characteristics on CVD death risk. Results: The study cohort comprised 59,726 patients, followed for an average of 36.7 months. Non-small cell lung cancer (NSCLC) [adjusted hazard ratio (HR) =1.652, 95% confidence interval (CI): 1.359 to 2.008, P<0.001], localized stage (adjusted HR =3.273, 95% CI: 2.924 to 3.663, P<0.001), and regional stage (adjusted HR =2.177, 95% CI: 1.939 to 2.443, P<0.001) were significantly associated with higher risk of CVD death in CT/RT-treated lung cancer patients. The associations remained consistent across subgroup analyses. The nomogram demonstrated moderate discrimination and good calibration. Significant differences were observed across risk groups (P<0.001). Conclusions: NSCLC, localized and regional stages were associated with higher risk of CVD death in CT/RT-treated lung cancer patients. Targeted strategies for CVD management are needed for these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.